Medical oncologists provide insights on the evolving molecular testing practices for NRG1 fusions.
Educational support for this activity provided by Merus.
Pelareorep Combination Shows Manageable Safety in Metastatic Pancreatic Cancer
January 25th 2025Cohort 5 of the ongoing phase 1/2 GOBLET study evaluated the safety of pelareorep in combination with modified FOLFIRINOX with or without atezolizumab in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma.